Skip to main content
TipRanks
Go Ultimate75% OFF

TenNor Therapeutics Suzhou Ltd. Class H (6872) Stock Price & Analysis

6872 Stock Chart & Stats

HK$67.85-HK$0.75(-1.09%)
At close: 4:00 PM GMT+8
HK$100HK$150HK$200Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2Nov 16
Day’s Range
HKD 64.10 - HKD 68.30
52-Week Range
HKD 62.25 - HKD 287.00
Previous Close
HKD 68.60
Volume
N/A
Average Volume (3M)
79.78K
Market Cap
HKD 3.55B
Enterprise Value
HKD 10.69B
Total Cash (Recent Filing)
HKD 183.76M
Total Debt (Recent Filing)
HKD 28.65M
Price to Earnings (P/E)
―
Beta
-0.38
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Modest Leverage

The relatively low debt burden provides more financial flexibility than a highly leveraged balance sheet would. With debt modest relative to equity, the company may have greater capacity to sustain research spending and manage obligations while it works toward commercial development.

Positive Equity Restoration

Returning to positive equity is an important improvement in financial resilience after two years of balance-sheet weakness. Although losses remain substantial, the change gives the company a stronger reported capital position and reduces the immediate fragility associated with negative shareholders’ equity.

Temporary Loss And Burn Improvement

The 2024 improvement in both reported loss and operating cash burn shows that the company has demonstrated some ability to reduce financial pressure. While the benefit was not sustained in 2025, this remains evidence that spending and cash usage can improve under favorable operating conditions.

Bears Say

No Commercial Revenue

The absence of revenue over three consecutive years indicates that TenNor has not yet established visible commercial traction. Without product sales, the business remains dependent on funding and continued development progress, leaving future financial performance highly uncertain over the coming quarters.

Persistent Large Losses

Recurring large net losses show that the current operating model does not yet support self-funded growth. The slight deterioration in 2025 after improvement in 2024 also provides limited evidence of a durable narrowing trend, keeping profitability a distant and uncertain milestone.

Sustained Cash Burn

Persistent negative operating and free cash flow means reported losses are translating into substantial cash outflows rather than being offset by non-cash items. The renewed increase in 2025 burn could heighten funding needs and constrain the company’s ability to finance development internally.

TenNor Therapeutics Suzhou Ltd. Class H News

6872 FAQ

What was TenNor Therapeutics Suzhou Ltd. Class H’s price range in the past 12 months?
TenNor Therapeutics Suzhou Ltd. Class H lowest stock price was HK$62.25 and its highest was HK$287.00 in the past 12 months.
What is TenNor Therapeutics Suzhou Ltd. Class H’s market cap?
TenNor Therapeutics Suzhou Ltd. Class H’s market cap is HK$3.55B.
When is TenNor Therapeutics Suzhou Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TenNor Therapeutics Suzhou Ltd. Class H’s earnings last quarter?
TenNor Therapeutics Suzhou Ltd. Class H released its earnings results on Aug 26, 2026. The company reported -HK$1.4 earnings per share for the quarter.
Is TenNor Therapeutics Suzhou Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does TenNor Therapeutics Suzhou Ltd. Class H pay dividends?
TenNor Therapeutics Suzhou Ltd. Class H does not currently pay dividends.
What is TenNor Therapeutics Suzhou Ltd. Class H’s EPS estimate?
TenNor Therapeutics Suzhou Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TenNor Therapeutics Suzhou Ltd. Class H have?
TenNor Therapeutics Suzhou Ltd. Class H has 52,328,926 shares outstanding.
What happened to TenNor Therapeutics Suzhou Ltd. Class H’s price movement after its last earnings report?
TenNor Therapeutics Suzhou Ltd. Class H reported an EPS of -HK$1.4 in its last earnings report. Following the earnings report the stock price went up 1.35%.
Which hedge fund is a major shareholder of TenNor Therapeutics Suzhou Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6872
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology